美国首例耳道假丝酵母菌案例报道
First cases of Candida auris reported in United States资料来源于NHSN(美国CDC）网站：https://www.cdc.gov/media/releases/2016/p1104-candida-auris.html 美国首例耳道假丝酵母菌案例报道 该报告是第一个描述美国的耳道假丝酵母菌的案例。耳道假丝酵母菌通常对抗真菌药物具有抗性，并且倾向于在住院患者中发生。在2016年6月，CDC发布了一个临床警报，描述了耳道假丝酵母菌的全球性出现，并要求实验室报告耳道假丝酵母菌病例，并向国家和地方卫生部门和CDC发送患者样本。从那时起，CDC一直在调查与几个州和地方卫生部门的耳道假丝酵母菌的报告。该机构预计将继续调查可能的病例，因为对新出现的感染的认识增加。在报告中详细描述的7个病例中，在四个州报告了耳道假丝酵母菌的患者：纽约，伊利诺伊州，马里兰州和新泽西州。所有患者都有严重的基础性疾病，并且有平均18天的住院时间，才确定耳道假丝酵母菌。其中四名病人死亡;目前还不清楚这些死亡是否与耳道假丝酵母菌感染或潜在的健康状况有关。 来自美国患者的大多数耳道假丝酵母菌菌株（71％）显示出一些耐药性，使得治疗更困难。已经发现来自其他国家的耳道假丝酵母菌菌株的样品对所有三种主要类型的抗真菌药物具有抗性。然而，在本报告中没有一个美国菌株对所有三种抗真菌药物类型有抗性。基于实验室测试，发现美国菌株与来自南亚和南美洲的菌株有关。然而，没有一个患者曾经前往或与这些区域有任何直接联系。大多数患者可能在本地获得感染。 Thirteen cases of Candida auris (C. auris), a serious and sometimes fatal fungal infection that is emerging globally, have been identified in the United States, according to the Centers for Disease Control and Prevention (CDC). Seven of the cases occurred between May 2013 and August 2016 and are described today in CDC’s Morbidity and Mortality Weekly Report (MMWR). The other six cases were identified after the period covered by the report and are still under investigation.The report is the first to describe U.S. cases of C. auris infection. C. auris is often resistant to antifungal drugs and tends to occur in hospitalized patients. In June 2016, CDC issued a clinical alert describing the global emergence of C. auris and requesting that laboratories report C. auris cases and send patient samples to state and local health departments and CDC. Since then, CDC has been investigating reports of C. auris with several state and local health departments. The agency expects to continue to investigate possible cases as awareness of the emerging infection increases.
学习了，这个咱们官微也推送过 提醒我们也要关注，这个季节，由于暖气的使用，真菌也开始肆虐了！
页:
[1]